Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?
01:01pm, Tuesday, 14'th Oct 2025
Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
08:30am, Thursday, 09'th Oct 2025
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
06:00am, Thursday, 09'th Oct 2025
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On
06:09pm, Tuesday, 02'nd Sep 2025
I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
12:30pm, Tuesday, 02'nd Sep 2025
Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.
Zymeworks halts development of cancer drug after trial setback
06:18am, Tuesday, 02'nd Sep 2025
Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
06:00am, Tuesday, 02'nd Sep 2025
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 19'th Aug 2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 12'th Aug 2025
Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
06:00am, Monday, 11'th Aug 2025
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
04:33pm, Friday, 08'th Aug 2025
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
07:35pm, Thursday, 07'th Aug 2025
Zymeworks Inc. (ZYME) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $0.26 per share a year ago.
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
